Limited benefit of ASCT for relapsed DLBCL. In the rituximab era, the ultimate benefit of HD-ASCT is limited. For 300 patients diagnosed with DLBCL, 200 will be cured with up-front therapy. Of the 100 who relapse, at least half are unlikely to be eligible for aggressive approaches due to advanced age, comorbidities, social and access issues, or individual choice. Therefore, only 50 of these patients can be approached with curative intent. Based on the results of CORAL study, because these patients have had previous rituximab exposure, the response rate to salvage therapy is only 51%; therefore, at most, 25 patients will undergo ASCT. The 3-year PFS of those treated with ASCT is 40%, so only 10 patients of the original 300 de novo patients or the 100 relapsed patients are ultimately cured of lymphoma with HD-ASCT.